MCK
NYSEMcKESSON CORPORATION
Consumer Defensive · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Research view
Fundamentals · SEC EDGAR · FY 2026-03-31
Revenue & Earnings — fiscal year
$264.0B
2022
$276.7B
2023
$309.0B
2024
$359.1B
2025
$403.4B
2026
Snapshot
SEC EDGAR · FY 2026-03-31Revenue$403.4B
Net Income$5.1B
Gross Profit$14.6B
Oper Income$6.2B
EPS (dil)$38.38
Rev/sh$3356.21
FCF/sh$47.58
Book/sh$-14.78
Gross M3.6%
Oper M1.5%
Profit M1.3%
FCF M1.4%
ROE-286.9%
ROA6.2%
ROIC209.2%
R&D/Rev0.0%
Rev Y/Y12.4%
Rev 3Y CAGR13.4%
EPS Y/Y49.2%
EPS 3Y CAGR15.3%
FCF 3Y CAGR6.2%
Payout8%
Div/sh$3.17
Shs Chg Y/Y-3.1%
Current Ratio0.85
Quick Ratio0.49
Debt/Eq-4.66
Int Coverage25.1×
Net Debt$4.2B
Total Debt$8.3B
Cash & Eq$4.1B
Total Assets$82.3B
Oper CF$6.2B
Capex$436.0M
Free CF$5.7B
Buybacks$4.8B
Equity$-1.8B
Liabilities—
Shs Outstand0.12B
SectorConsumer Defensive
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $264.0B | $276.7B | $309.0B | $359.1B | $403.4B |
| Gross Profit | $13.1B | $12.4B | $12.8B | $13.3B | $14.6B |
| Operating Income | $2.0B | $4.4B | $3.9B | $4.4B | $6.2B |
| Net Income | $1.3B | $3.7B | $3.2B | $3.5B | $5.1B |
| Diluted EPS | $7.23 | $25.03 | $22.39 | $25.72 | $38.38 |
| Operating Cash Flow | $4.4B | $5.2B | $4.3B | $6.1B | $6.2B |
| Free Cash Flow | $4.0B | $4.8B | $3.9B | $5.5B | $5.7B |
COMMUNITY · $MCK0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.